Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $210
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $174 to $210.
Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $174 to $210.